The Vogue Review of Haruharu Wonder's PDRN Serum Skips the Fine Print on What PDRN Actually Does

Vogue España's write-up on the Haruharu Wonder Rose PDRN serum describes a nighttime product that promises radiant, renewed skin through "100% natural" action. The article does not specify which of the brand's two Rose PDRN serums it covers. Haruharu Wonder sells a Soothing Serum built around vegan rose-derived PDRN, azelaic acid, niacinamide and ceramides for redness-prone skin, and a separate Firming Serum that relies on retinal, peptides, niacinamide and centella for anti-aging claims. The two products target different skin concerns and carry different active ingredients, so a reader trying to match the article's promises to a specific bottle on a shelf has no way to confirm which formula is being described.

The bigger gap sits with PDRN itself. Polydeoxyribonucleotide is a purified DNA-fragment ingredient traditionally extracted from salmon or trout roe, and Haruharu Wonder markets a plant-derived version sourced from Damascus rose stem cells instead. That substitution is itself a response to consumer unease about the ingredient's origins in a category sometimes nicknamed "salmon sperm skincare." The reformulation is worth noting on its own terms, since it swaps a well-documented animal-derived compound for a plant alternative whose penetration and activity have not been studied to the same degree.

The evidence for PDRN's regenerative effects comes almost entirely from injectable use. Korean clinics have used injectable PDRN, popularized under the brand name Rejuran, for wound healing and skin regeneration since around 2014, and a 2023 survey by Kim and colleagues found that roughly 88% of practitioners ranked PDRN boosters among the most in-demand injectable treatments. Dermatologists interviewed by Marie Claire UK about the current wave of PDRN serums were blunt about what that evidence does and does not cover for topical products: the PDRN molecule is considered too large to penetrate the skin barrier in a serum format, meaning any benefit a jar or dropper delivers is likely limited to surface hydration rather than the collagen stimulation associated with injections.

Ingredient suppliers have an answer for that objection. Some now promote "low-molecular-weight PDRN" formulations designed to cross the barrier more effectively, but that research originates from the suppliers marketing the raw material, not from independent clinical trials. NBC News Select's reporting on the trend lands in the same place: topical PDRN has consumer enthusiasm and retail momentum behind it, but the clinical data backing injectable PDRN has not been replicated for the serums sitting on drugstore and Target shelves.

That retail momentum is real and substantial. On Olive Young, Korea's largest beauty retailer, PDRN appeared in 33 of the top 50 "skin longevity" products tracked between October 2025 and March 2026, trailing only hyaluronic acid in prevalence, according to data cited by in-cosmetics connect. Haruharu Wonder's own Rose PDRN serum is riding that wave into a new market: the brand launched nationwide at Target on January 5, 2026, with products priced under $25, according to coverage in GCI Magazine and Mann Publications. The company describes itself as female-founded, built around a fermentation process it says runs more than 400 hours, with distribution in over 150 countries through more than 90 retail partners.

None of that context appears in the Vogue España piece, which presents the serum's nighttime ritual and ingredient list without addressing where its core active ingredient's clinical support actually comes from. The serum may still do what a good moisturizer does: hold water at the skin's surface and calm visible redness overnight. What it has not been shown to do, at least not in any study independent of an ingredient supplier's own data, is replicate the regenerative effects documented for the injectable version sold in clinics under the Rejuran name.